Why the MGC Pharma (ASX:MXC) share price is zooming 13% higher today

The MGC Pharma (ASX: MXC) share price is up 13% in morning trade. We look at the latest from the ASX cannabis share.

| More on:
cannabis leaves on a rising line graph representing growth of ASX cannabis share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The MGC Pharmaceuticals Ltd (ASX: MXC) share price is off to the races today, up 13% at the time of writing.

The bio-pharma company produces and develops cannabis-derived medicines.

Let's take a look at the ASX cannabis share's latest product orders and revenue stream.

What did MGC Pharma report today?

The MGC Pharma share price is rocketing higher after the company reported it had completed the delivery of its first bulk order of ArtemiC Rescue in March to Swiss PharmaCan AG. The bulk order of its medicinal food supplement delivered approximately $425,000 in wholesale production revenue.

Swiss PharmaCan's purchase helped drive MGC Pharma to record quarterly sales revenue from its "proprietary phytomedicine product line". The ASX cannabis share reported it had generated roughly $880,000 of revenue during the March 2021 quarter.

The company also said March brought in its best single month's sales revenue so far from its pharmaceutical-grade phytomedicine products, driven by sales of its MP product line in Australia.

Words from the management

Commenting on the results, MGC Pharma global chief sales officer Nicole Godresse said:

In recent months we have seen rapid sales growth of our medical cannabis products as a direct result of our strategy to broaden our core prescriber base, diversify and expand our revenue streams and build additional strategic alliances. It is pleasing to see these strategies starting to translate into positive commercial outcomes and we expect this strong growth momentum to continue in 2021 and beyond.

MGC Pharma managing director Roby Zomer added:

We are very pleased to complete our first batch purchase order for ArtemiC Rescue under our Swiss PharmaCan agreement. This, combined with sales growth of other pharma grade cannabinoid products in key markets, has helped to deliver the strongest month and quarter of revenue growth for the company to date.

MGC Pharma's detailed March quarterly activity report is expected within the next few weeks.

MGC Pharma share price snapshot

Over the past 12 months, the MGC Pharma share price has gained 130%, handily outpacing the 35% gains posted by the All Ordinaries Index (ASX: XAO) over that same period.

With today's intraday gains factored in, the MGC Pharma share price is up 245% year-to-date.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Family having fun while shopping for groceries.
Consumer Staples & Discretionary Shares

2 ASX consumer staples shares to sell now: experts

Two experts are now calling for investors to sell two of the largest ASX consumer staples shares on the market.

Read more »

Business man at desk looking out window with his arms behind his head at a view of the city and stock trends overlay.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Man leaps as he runs along the street.
Share Gainers

3 ASX 200 stocks storming higher in this week's falling market

These three ASX 200 stocks are leaping higher this week despite the broader market retrace. But why?

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Share Fallers

Why Alliance, Block, DroneShield, and Macquarie shares are tumbling today

These shares are ending the week in the red. But why?

Read more »

Businessman looks with one eye through magnifying glass
Broker Notes

Macquarie tips 37% upside for Steadfast shares

Analysts see brighter days ahead for this insurance heavyweight after a sharp pullback in October.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Share Gainers

Why ASX, Lynas, News Corp, and Solvar shares are storming higher today

These shares are ending the week on a high. Let's find out why.

Read more »

A young man talks tech on his phone while looking at a laptop. A financial graph is superimposed across the image.
Broker Notes

Macquarie tips 17% return for this high-flying ASX 200 stock

Let's see why the broker is feeling bullish about this stock.

Read more »

A young couple sits at their kitchen table looking at documents with a laptop open in front of them.
Share Market News

Light & Wonder expands buy-back to ASX CDIs: Key details for shareholders

Light & Wonder is extending its US$1.5bn buy-back to ASX-listed CDIs, with around US$705m capacity remaining.

Read more »